Merck and Moderna's Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence in 1,137-Patient Phase 3 Trial
Merck and Moderna said on August 20 that intismeran autogene, a personalized mRNA cancer vaccine, met its primary endpoint in a 1,137-patient Phase 3 trial in high-risk melanoma. The result is the first late-stage clinical validation of personalized mRNA oncology and clears the path for regulatory filings in Q4.